Stay updated on Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.

Latest updates to the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded New York as a study location under Locations and updated the page to revision v3.3.3. The previous 'New York Locations' entry and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check55 days agoChange DetectedThe revision label updated from v3.2.0 to v3.3.2. No study-related content appears to be altered.SummaryDifference0.1%

- Check63 days agoChange DetectedThe government funding notice about potential delays and operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedTwo screenshots show the same study page with no significant additions or deletions; any visible differences are minor formatting changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check106 days agoChange Detected- Version updated from v3.1.0 to v3.2.0. - Added a prominent notice about government funding lapse and potential delays, and directing users to operating-status resources (cc.nih.gov, opm.gov).SummaryDifference3%

Stay in the know with updates to Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.